趋化因子受体CCR6及CCR7在乳腺癌组织上的表达及其意义

Expression of chemokine receptor CCR6 and CCR7 in breast cancer and its clinical significance

目的探讨趋化因子受体CCR6及CCR7在乳腺癌组织中的表达及其意义。方法用免疫组织化学方法检测45例乳腺癌及10例乳腺纤维腺瘤组织中趋化因子受体CCR6及CCR7的表达,并对原位癌及发生转移的癌组织CCR6及CCR7的表达率进行比较。结果在乳腺癌组织上检测到趋化因子受体CCR6及CCR7的表达(表达率分别为35.6%和48.9%),其中发生转移的癌组织CCR6及CCR7的表达率分别为41.7%和55.6%,未发生转移的癌组织CCR6及CCR7的表达率分别为11.1%和22.2%,乳腺纤维腺瘤组织中未发现CCR6及CCR7的表达。结论乳腺癌组织上有趋化因子受体CCR6及CCR7的表达,其表达可能在乳腺癌的发生、发展和转移中发挥作用。

Objective To explore the expression of ehernokine receptor CCR6 and CCR7 in breast cancer tissue and its clinical significance. Methods Forty five cases of breast cancer specimens and ten cases of breast fibroadenoma specimens were analyzed by immunohistochemical staining for CCR6 and CCR7 expression. The rates of CCR6 and CCR7 expression were compared between primary and metastastic breast cancer tissue. Results The expression of CCR6 and CCR7 was detected in breast cancer （the positive rates were 35.6 % and 48.9% respectively）. The CCR6 and CCR7 expres sion rates in primary and metastastic breast cancer tissue were 11.1%, 22.2% and 41.7%, 55.6% respectively, while CCR6 and CCR7 were not detected in breast fibroadenoma specimens. Conclusion CCR6 and CCR7 express in human breast cancer tissue, and they may play an important role in the occurrence, development and metastasis of human breast cancer.